It’s funny that they are fully funded all the way into phase 2 with non dilutive funding extending the companies funds well into phase 2 and the market cap is now trading below it’s coming up cash funding pricing nothing in for how de risked the drug is heading into phase 1 and phase 2 FDA approval. AGN is looking like on any good news will become a 200-300 million dollar company on the potential of the drug.
- Forums
- ASX - By Stock
- Ann: Significant Neuroprotection in NYR Preclinical Brain Injury
It’s funny that they are fully funded all the way into phase 2...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NYR (ASX) to my watchlist
|
|||||
Last
5.7¢ |
Change
0.001(1.79%) |
Mkt cap ! $10.38M |
Open | High | Low | Value | Volume |
5.6¢ | 5.8¢ | 5.5¢ | $23.44K | 412.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 207248 | 5.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.9¢ | 72456 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 207248 | 0.057 |
1 | 54550 | 0.055 |
2 | 315000 | 0.054 |
1 | 138415 | 0.053 |
2 | 28159 | 0.052 |
Price($) | Vol. | No. |
---|---|---|
0.059 | 72456 | 3 |
0.060 | 7000 | 1 |
0.061 | 163950 | 1 |
0.064 | 24864 | 1 |
0.069 | 33333 | 1 |
Last trade - 13.08pm 27/06/2024 (20 minute delay) ? |
Featured News
NYR (ASX) Chart |